22nd Annual Federation of Clinical Immunology Societies (FOCIS) Meeting 2022– Abstract and Poster Presentation

Jun 23, 2022

Th42 – Next-generation Immunostimulatory Antibody-drug Conjugate (iADC) Combines Direct Tumor Killing and Innate Immune Stimulation to Provide Protective Anti-Tumor Immunity

Presenting Author:

Kristin Bedard, PhD
VP Discovery
Sutro Biopharma
South San Francisco, California, United States

Abstract Text: In recent years, combination therapies of antibody-drug conjugates (ADCs) and immune system activators have garnered much interest due to their potential to unlock greater durable clinical benefit. Recently, we demonstrated that STRO-002, our novel anti-folate receptor alpha (Folα)ADC currently in Phase I clinical trials, can engage the immune system through induction of immunogenic cell death (ICD). We further showed that by complementing the ICD-inducing property of STRO-002 with combination treatment with Avelumab, we could enhance infiltration of CD8+ T cells into the tumor and generate potent anti-tumor immunity. To develop the combination concept further, we leveraged Sutro’s breakthrough XpressCF+TM cell-free technology, which utilizes precise site-specific conjugation to generate complex molecules, to engineer the immunostimulatory ADC (iADC), a next-generation ADC molecule that combines tumor-targeted cell killing and immune activation in a single modality. Using murine MC38 tumors engineered to express human FolRα, we demonstrated that delivery of a hemiasterlin/TLR agonist dual-conjugate anti-FolRα iADC resulted in a more robust anti-tumor response compared to either modality administered alone. This improved response was associated with innate immune cell activation and increased CD8+ T cell infiltration in the tumor. Moreover, a greater number of complete responses was also observed following treatment with the anti-FolRα iADC, and complete responders developed broad and robust immune memory that was able to reject MC38-hFolRα rechallenge in a CD8+ T cell-dependent manner and parental MC38 rechallenge. Thus, the iADC concept unites two complementary mechanisms of tumor control in a single molecule to attain greater therapeutic benefit.

22nd Annual Meeting of the Federation of Clinical Immunology Societies (FOCIS) – Abstract and Poster Presentation
Sutro Biopharma, Inc.
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.